Paclitaxel liposome encapsulated - INSYS Therapeutics

Drug Profile

Paclitaxel liposome encapsulated - INSYS Therapeutics

Alternative Names: LEP; LEP-ETU; Liposome encapsulated paclitaxel; Liposome entrapped paclitaxel; NeoLipid™ paclitaxel; ONC 0355; Paclitaxel liposomal - INSYS Therapeutics; PNU 914; PNU 93914

Latest Information Update: 28 May 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Georgetown University
  • Developer INSYS Therapeutics, Inc
  • Class Antineoplastics; Diterpenes; Paclitaxels; Small molecules; Taxanes
  • Mechanism of Action Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gastric cancer; Ovarian cancer
  • New Molecular Entity No

Highest Development Phases

  • Phase II Cervical cancer; Cholangiocarcinoma
  • No development reported Breast cancer; Gastric cancer; Ovarian cancer

Most Recent Events

  • 28 May 2018 No recent reports of development identified for preclinical development in Gastric-cancer in USA (IV)
  • 28 May 2018 No recent reports of development identified for preclinical development in Ovarian-cancer in USA (IV)
  • 18 Oct 2016 Phase-II clinical trials in Cervical cancer in USA (IV) (INSYS Therapeutics pipeline October 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top